SON-1010 + Atezolizumab combo Demonstrates a Strong Safety Profile in Platinum-Resistant Ovarian Cancer patients April 15, 2025
SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer April 8, 2025
FAILED TRIAL: Ph 3 ARTISTRY-7 Trial of Nemvaleukin + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer did not achieve a statistically significant improvement in OS April 2, 2025
Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer April 2, 2025
Ph 3 Study Design Finalized with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer April 2, 2025
SGO 2025: ELAHERE (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients March 18, 2025
SGO 2025: Updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC announced March 18, 2025
SGO 2025: Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer Presented March 18, 2025
SGO 2025: Rinatabart Sesutecan (Rina-S) Shows Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer March 18, 2025
Translational Data Announced from Ph 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer February 25, 2025
FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer February 19, 2025
Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T) for Advanced Ovarian Cancer February 11, 2025
Ongoing Ph 2 trial expanded to optimize stenoparib dose and refine DRP® patient selection criteria February 10, 2025
Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer February 4, 2025
FDA Acceptance and Priority Review of NDA for Avutometinib + Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer Announced January 7, 2025
FAILED TRIAL: FIRST trial of Jemperli (dostarlimab) + chemo and Zejula maintenance +/- avastin met primary endpoint of PFS but not OS in 1L advanced ovarian cancer December 25, 2024
Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer Announced December 25, 2024
Continued Strong Improvement in OS Data from Ph 2 OVATION 2 Study of IMNN-001 Announced December 18, 2024
Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph 1 Gynecologic Expansion Clinical Trial Announced December 18, 2024
FAILED TRIAL: Ph 3 KEYLYNK-001 Trial Met Primary Endpoint of PFS, but not OS, in Patients With Advanced Epithelial Ovarian Cancer December 10, 2024
Results from End-of-Phase 2 Meeting with FDA for IMNN-001 Program in Advanced Ovarian Cancer Announced November 26, 2024
